Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins

Journal of Pharmaceutical Sciences

Volumn 94, Issue 8, 2005, Pages 1626-1635

  Sinclair, Angus M ^a   Elliott, Steve ^a  

^a AMGEN INC   (United States)

Author keywords

Aranesp ; Darbepoetin alfa; Drug design; Erythropoietin; Glycoprotein; Glycosylation; Immunogenicity; Serum half life; Sialic acid; Solubility; Stability

Indexed keywords

ALPHA2B INTERFERON; ASIALOGLYCOPROTEIN; BETA INTERFERON; ERYTHROPOIETIN; FOLLITROPIN; HEMOGLOBIN; INTERLEUKIN 5; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN MPL; RECOMBINANT BETA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 3; RECOMBINANT LEPTIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG HALF LIFE; DRUG SOLUBILITY; GLYCOGENOLYSIS; GLYCOSYLATION; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; INFERTILITY; MOLECULAR STABILITY; NONHUMAN; PROTEIN ENGINEERING; PROTEIN FOLDING; SHORT SURVEY;

EID: 25444435396     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20319     Document Type: Short Survey

References (69)

1. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. 2003. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421.
2. Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E, Stebbing N. 1986. Erythropoietin: Gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 51:693-702.
3. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z. 1985. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82: 7580-7584.
4. Egrie JC, Browne J, Lai P, Lin FK. 1985. Characterization of recombinant monkey and human erythropoietin. Prog Clin Biol Res 191:339-350.
5. Egrie JC, Browne JK. 2001. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84:3-10.
6. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. 2003. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299.
7. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. 1999. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395.
8. Imperiali B, Hendrickson TL. 1995. Asparagine-linked glycosylation: Specificity and function of oligosaccharyl transferase. Bioorg Med Chem 3:1565-1578.
9. Rudd PM, Dwek RA. 1997. Glycosylation: Heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32:1-100.
10. Plante OJ, Seeberger PH. 2003. Recent advances in automated solid-phase carbohydrate synthesis: From screening to vaccines. Curr Opin Drug Discov Dev 6:521-525.
11. Van den Steen P, Rudd PM, Dwek RA, Van Damme J, Opdenakker G. 1998. Cytokine and protease glycosylation as a regulatory mechanism in inflammation and autoimmunity. Adv Exp Med Biol 435:133-143.
12. Hansen JE, Lund O, Engelbrecht J, Bohr H, Nielsen JO, Hansen JE. 1995. Prediction of O-glycosylation of mammalian proteins: Specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem J 308:801-813.
13. Thanka Christlet TH, Veluraja K. 2001. Database analysis of O-glycosylation sites in proteins. Biophys J 80:952-960.
14. Elliott S, Bartley T, Delorme E, Derby P, Hunt R, Lorenzini T, Parker V, Rohde MF, Stoney K. 1994. Structural requirements for addition of O-linked carbohydrate to recombinant erythropoietin. Biochemistry 33:11237-11245.
15. Kirnarsky L, Nomoto M, Ikematsu Y, Hassan H, Bennett EP, Cerny RL, Clausen H, Hollingsworth MA, Sherman S. 1998. Structural analysis of peptide substrates for mucin-type O-glycosylation. Biochemistry 37:12811-12817.
16. Van den Steen P, Dwek RA, Opdenakker G. 1998. Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol 33:151-208.
17. Bause E. 1983. Structural requirements of N-glycosylation of proteins. Studies with proline peptides as conformational probes. Biochem J 209: 331-336.
18. Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54:631-664.
19. Gavel Y, von Heijne G. 1990. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: Implications for protein engineering. Protein Eng 3:433-442.
20. Apweiler R, Hermjakob H, Sharon N. 1999. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta 1473:4-8.
21. Elliott S, Chang D, Delorme E, Eris T, Lorenzini T. 2004. Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. J Biol Chem 279:16854-16862.
22. Nilsson IM, von Heijne G. 1993. Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. J Biol Chem 268:5798-5801.
23. Kalies KU, Hartmann E. 1998. Protein translocation into the endoplasmic reticulum (ER)-Two similar routes with different modes. Eur J Biochem 254:1-5.
24. Sasaki H, Bothner B, Dell A, Fukuda M. 1987. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262:12059-12076.
25. Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rhode MF, Katta V. 1995. Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 15:1442-14452.
26. Takeuchi M, Kobata A. 1991. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:337-346.
27. Elliott S, Egrie J, Browne J, Lorenzini T, Rogers N, Ponting I. 2004. Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol 32:1146-1155.
28. Bernard BA, Yamada KM, Olden K. 1982. Carbohydrates selectively protect a specific domain of fibronectin against proteases. J Biol Chem 257: 8549-8554.
29. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15:641-649.
30. Kodama S, Tsujimoto M, Tsuruoka N, Sugo T, Endo T, Kobata A. 1993. Role of sugar chains in the in vitro activity of recombinant human interleukin 5. Eur J Biochem 211:903-908.
31. Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R. 1990. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 188:405-411.
32. Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW. 1991. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266:23022-23026.
33. Endo Y, Nagai H, Watanabe Y, Ochi K, Takagi T. 1992. Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem 112:700-706.
34. Uchida E, Morimoto K, Kawasaki N, Izaki Y, Abdu SA, Hayakawa T. 1997. Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic Res 27:311-323.
35. Goochee CF, Gramer M, Andersen D, Bahr J, Rasmussen JR. 1991. The oligosaccharides of glycoproteins: Factors affecting their synthesis and their influence on glycoprotein properties. In: Sikdar SK, Brier M, Todd P, editors. Frontiers in bioprocessing II. Washington DC: American Chemical Society, pp 199-240.
36. Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. 2002. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA 99:339-344.
37. Sasu B, Hartley C, Schultz H, McElroy P, Khaja R, Elliott S, Egrie J, Browne JK, Begley CG, Molineux G. 2003. Has the Unit of erythropoietic activity outlived its usefulness? Blood 102:4386
38. Hartley C, Elliott S, Begley CG, McElroy P, Sutherland W, Khaja R, Heatherington AC, Graves T, Schultz H, Del Castillo J, Molineux G. 2003. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: Optimized erythroid support with darbepoetin alpha. Br J Haematol 122:623-636.
39. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432.
40. Kuter DJ. 2004. Thrombopoietin factors. In: Morstyn G, Foote M, Lieschke GJ, editors. Hematopoietic growth factors in oncology. Totowa, NJ: Humana Press, pp 125-152.
41. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S. 1994. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mp1. Cell 77:1117-1124.
42. Hunt P, Li YS, Nichol JL, Hokom MM, Bogenberger JM, Swift SE, Skrine JD, Hornkohl AC, Lu H, Clogston C. 1995. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 86:540-547.
43. Elliott S, Heatherington AC, Toote M. 2004. Erythropoietic factors. In: MorstynG Foote M, Lieschke GJ. editors. Hematopoietic growth factors in oncology. Totowa, NJ: Humana Press, pp 97-124.
44. Glaspy J, Henry D, Patel R, Tchekmedyian S, Berg R, Rossi G, Austin M. 2003. A randomized trial evaluating the pharmacologic and hematologic effects of the timing of darbepoetin alfa and chemotherapy administration. Blood 102:9b.
45. Creus S, Chaia Z, Pellizzari EH, Cigorraga SB, Ulloa-Aguirre A, Campo S. 2001. Human FSH isoforms: Carbohydrate complexity as determinant of in-vitro bioactivity. Mol Cell Endocrinol 174: 41-49.
46. D'Antonio M, Borrelli F, Datola A, Bucci R, Mascia M, Polletta P, Piscitelli D, Papoian R. 1999. Biological characterization of recombinant human follicle stimulating hormone isoforms. Hum Reprod 14:1160-1167.
47. Perlman S, van den HB, Christiansen J, Gram-Nielsen S, Jeppesen CB, Andersen KV, Halkier T, Okkels S, Schambye HT. 2003. Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab 88:3227-3235.
48. Ziltener HJ, Clark-Lewis I, Jones AT, Dy M. 1994. Carbohydrate does not modulate the in vivo effects of injected interleukin-3. Exp Hematol 22:1070-1075.
49. Clarenburg R. 1983. Asialoglycoprotein receptor is uninvolved in clearing intact glycoproteins from rat blood. Am J Physiol 244:G247-G253.
50. Ishibashi S, Hammer RE, Herz J. 1994. Asialoglycoprotein receptor deficiency in mice lacking the minor receptor subunit. J Biol Chem 269:27803-27906.
51. Tozawa R, Ishibashi S, Osuga J, Yamamoto K, Yagyu H, Ohashi K, Tamura Y, Yahagi N, Iizuka Y, Okazaki H, Harada K, Gotoda T, Shimano H, Kimura S, Nagai R, Yamada N. 2001. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit. Its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem 276:12624-12628.
52. Jensen JD, Jensen LW, Madsen JK, Poulsen L. 2004. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 54:111-116.
53. Sawyer ST, Krantz SB, Goldwasser E. 1987. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554-5562.
54. Heatherington AC. 2003. Clinical pharmacokinetic properties of rHuEPO: A review. In: Molineux G, Foote M, Elliott S, editors. Erythropoietins and erythropoiesis-Molecular, cellular, preclinical and clinical biology. Basel, Switzerland: Birkhauser-Verlag. pp 87-112.
55. Zang YCQ, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. 2000. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 55:397-404.
56. Oberg K, Norheim I, Alm G. 1989. Treatment of malignant carcinoid tumors: A randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol 25:1475-1479.
57. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med 346:469-475.
58. Mayeux P, Casadevall N. 2003. Antibodies to endogenous and recombinant erythropoietin. In: Molineux G, Foote MA, Elliott SG, editors. Erythropoietins and erythropoiesis. Basel, Switzerland: Birkhauser Verlag. pp 229-240.
59. Smalling R, Foote M, Molineux G, Swanson SJ, Elliott S. 2004. Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge. Biotechnol Annu Rev 10:237-250.
60. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51: 691-697.
61. Man NT, Cartwright AJ, Andrews KM, Morris GE. 1989. Treatment of human muscle creatine kinase with glutaraldehyde preferentially increases the immunogenicity of the native conformation and permits production of high-affinity monoclonal antibodies which recognize two distinct surface epitopes. J Immunol Methods 125:251-259.
62. Imperiali B, O'Connor SE. 1999. Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. Curr Opin Chem Biol 3:643-649.
63. Elliott S, Chang D, Delorme E, Dunn C, Egrie J, Giffin J, Lorenzini T, Talbot C, Hesterberg L. 1996. Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: Effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure. Blood 87:2714-2722.
64. Wide L, Wilkstrom B, Eriksson K. 2003. A new principle suggested for detection of darbepoetin-alpha (NESP) doping. Ups J Med Sci 108:229-239.
65. Fernandes AI, Gregoriadis G. 2001. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: Implication in its pharmacokinetics. Int J of Pharm 217:215-224.
66. Ho CL, Lin YL, Chen WC, Rocchi R, Piek T. 1998. Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties. Toxicon 36:217-221.
67. Reitter JN, Means RE, Desrosiers RC. 1998. A role for carbohydrates in immune evasion in AIDS. Nat Med 4:679-684.
68. van Drunen Littel-van den Hurk, Hughes G, Babiuk LA. 1990. The role of carbohydrate in the antigenic and immunogenic structure of bovine herpesvirus type 1 glycoproteins gI and gIV. J Gen Virol 71:2053-2063.
69. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E. 1992. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2:1405-1416.